Share Price | TriSalus Life Sciences, Inc. Stock Analysis & Recommendation

Q: Is TriSalus Life Sciences, Inc. technically bullish or bearish?

As of 18 August 2025, the technical trend for TriSalus Life Sciences, Inc. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD also shows mildly bullish. However, the daily moving averages are mildly bearish, and the Bollinger Bands on a monthly basis are bearish. The KST presents a mixed view with a weekly bearish signal and a mildly bullish monthly signal. Overall, there is no clear trend indicated by Dow Theory or OBV.In terms of performance, TriSalus has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -1.8% versus the S&P 500's 12.22%, and a one-year return of 6.49% compared to 17.14%. This suggests a weaker technical stance despite some mildly bullish indicators.

Q: Is TriSalus Life Sciences, Inc. overvalued or undervalued?

As of 9 February 2023, the valuation grade for TriSalus Life Sciences, Inc. moved from does not qualify to risky. The company appears to be overvalued given its negative financial ratios, including a price to book value of -5.93 and an EV to EBITDA of -7.25. The negative return on capital employed and return on equity further underscore the financial challenges facing the company.In comparison to its peers, TriSalus's P/E ratio is -5.43, while Altimmune, Inc. has a P/E of -6.19 and Harpoon Therapeutics, Inc. shows a much larger negative P/E of -28.51. The overall market sentiment reflects poorly on TriSalus, as evidenced by its recent stock performance, which has underperformed the S&P 500 across various time frames, including a 1-year return of -7.03% compared to the S&P 500's 10.26%.

Q: How big is TriSalus Life Sciences, Inc.?

Market Cap: As of Jun 18, TriSalus Life Sciences, Inc. has a market capitalization of 196.38 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, TriSalus reported net sales of 32.14 million and a net profit of -27.22 million.Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds stood at -25.89 million, while total assets were reported at 23.97 million.

Q: What does TriSalus Life Sciences, Inc. do?

Overview: TriSalus Life Sciences, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot: Most recent Net Sales: 9 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -10 Million (Quarterly Results - Mar 2025) Market-cap: USD 196.38 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.55 Return on Equity: 105.18% Price to Book: -5.71Contact Details: Registrar Address: Not available.

Q: Should I buy, sell or hold TriSalus Life Sciences, Inc.?

Based on the current information about TriSalus Life Sciences, Inc., it would be advisable to consider selling your shares. The company has a negative book value and exhibits weak long-term fundamental strength, which raises concerns about its financial health. Additionally, while it has shown a significant growth rate in net sales over the past five years, the overall performance has been flat recently, and the company's ability to service its debt is weak, indicated by a poor EBIT to interest ratio. The negative EBITDA further adds to the risk associated with the stock. Given these factors, it may be prudent to reassess your investment in TriSalus Life Sciences and consider selling rather than holding or buying more shares.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

716.99 k

Shareholding (Mar 2026)

FII

0.35%

Held by 13 FIIs

DII

99.65%

Held by 10 DIIs

Promoter

0.00%

Is TriSalus Life Sciences, Inc. technically bullish or bearish?

20-Sep-2025

As of August 18, 2025, TriSalus Life Sciences, Inc. shows a mildly bearish trend overall, with mixed technical indicators and underperformance compared to the S&P 500, reflecting a year-to-date return of -1.8% versus 12.22%.

View full answer

Is TriSalus Life Sciences, Inc. overvalued or undervalued?

25-Jun-2025

As of February 9, 2023, TriSalus Life Sciences, Inc. is considered a risky investment due to its negative financial ratios and underperformance compared to peers and the S&P 500.

View full answer

How big is TriSalus Life Sciences, Inc.?

22-Jun-2025

As of Jun 18, TriSalus Life Sciences, Inc. has a market capitalization of 196.38 million, with net sales of 32.14 million and a net profit of -27.22 million over the last four quarters. The company's shareholder's funds are -25.89 million, and total assets are 23.97 million.

View full answer

What does TriSalus Life Sciences, Inc. do?

22-Jun-2025

TriSalus Life Sciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $9 million and a net loss of $10 million as of March 2025, with a market cap of $196.38 million. Key metrics include a negative P/E ratio and a return on equity of 105.18%.

View full answer

Should I buy, sell or hold TriSalus Life Sciences, Inc.?

22-Jun-2025

Compare TriSalus Life Sciences, Inc. with Similar Stocks

Altimmune, Inc.Heron Therapeutics, Inc.Graphite Bio, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of 160.64% over the last 5 years

Risky -

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 236 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.38

Return on Equity

95.68%

Price to Book

-6.97

Revenue and Profits:

Net Sales:

9 Million

(Quarterly Results - Mar 2026)

Net Profit:

2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

5.97%

6 Months

-43.96%

1 Year

-24.16%

2 Years

-28.67%

3 Years

-61.11%

4 Years

-58.49%

5 Years

-58.45%

TriSalus Life Sciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

160.64%

EBIT Growth (5y)

-261.87%

EBIT to Interest (avg)

-16.13

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.55

Sales to Capital Employed (avg)

-4.85

Tax Ratio

0.03%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

27.39%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-6.97

EV to EBIT

-9.23

EV to EBITDA

-9.52

EV to Capital Employed

-11.80

EV to Sales

5.51

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 16 Schemes (8.59%)

Foreign Institutions

Held by 13 Foreign Institutions (0.35%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -32.58% vs 13.79% in Dec 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 115.31% vs 9.26% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8.90",
          "val2": "13.20",
          "chgp": "-32.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.30",
          "val2": "-3.10",
          "chgp": "-167.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.40",
          "val2": "1.50",
          "chgp": "-6.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "11.30",
          "val2": "-5.10",
          "chgp": "321.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1.50",
          "val2": "-9.80",
          "chgp": "115.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-945.20%",
          "val2": "-247.70%",
          "chgp": "-69.75%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 53.74% vs 58.92% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -30.67% vs 49.49% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "45.20",
          "val2": "29.40",
          "chgp": "53.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-26.30",
          "val2": "-35.20",
          "chgp": "25.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.50",
          "val2": "3.10",
          "chgp": "77.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6.80",
          "val2": "9.10",
          "chgp": "-174.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-39.20",
          "val2": "-30.00",
          "chgp": "-30.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-596.80%",
          "val2": "-1,228.80%",
          "chgp": "63.20%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

8.90

13.20

-32.58%

Operating Profit (PBDIT) excl Other Income

-8.30

-3.10

-167.74%

Interest

1.40

1.50

-6.67%

Exceptional Items

11.30

-5.10

321.57%

Consolidate Net Profit

1.50

-9.80

115.31%

Operating Profit Margin (Excl OI)

-945.20%

-247.70%

-69.75%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is -32.58% vs 13.79% in Dec 2025

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2026 is 115.31% vs 9.26% in Dec 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

45.20

29.40

53.74%

Operating Profit (PBDIT) excl Other Income

-26.30

-35.20

25.28%

Interest

5.50

3.10

77.42%

Exceptional Items

-6.80

9.10

-174.73%

Consolidate Net Profit

-39.20

-30.00

-30.67%

Operating Profit Margin (Excl OI)

-596.80%

-1,228.80%

63.20%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 53.74% vs 58.92% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -30.67% vs 49.49% in Dec 2024

All Annual Results

Company CV

About TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available